Bristol-Myers Squibb (BMS) has partnered with Transgene, an Illkirch Graffenstaden Cedex, France-headquartered biopharmaceutical company and a part of Institut Mérieux, for clinical research to evaluate the safety, tolerability, and efficacy of Transgene’s investigational therapeutic vaccine, TG4010, in combination with BMS’ anti-cancer drug, Opdivo (nivolumab), plus standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC). Opdivo is a blockbuster drug for BMS with 2016 sales of $3.77 billion.

Under the agreement, Transgene will be the sponsor of the trial, and BMS will provide Opdivo for use in the study. Opdivo, a programmed death-1 immune checkpoint inhibitor, is indicated in the US for treating unresectable or metastatic melanoma as a single agent, unresectable or metastatic melanoma in combination with Yervoy (ipilimumab), metastatic non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck, and locally advanced or metastatic urothelial carcinoma.

Source: Bristol-Myers Squibb